Celularity Announces FDA Clearance of CYNK-101

Article

Investigational New Drug application accepted for natural killer cell therapy.

Celularity Inc. today announced FDA has cleared its Investigational New Drug (IND) application for the use of CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients with first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to enhance antibody-dependent cellular cytotoxicity (ADCC) with approved and novel antibody therapeutics.

Read more about CYNK-101 here.

Recent Videos
James Foster
John Arena
James Foster
Navigating an Uncertain Regulatory Landscape
James Foster
Related Content